[go: up one dir, main page]

PE20120323A1 - Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib - Google Patents

Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib

Info

Publication number
PE20120323A1
PE20120323A1 PE2011001907A PE2011001907A PE20120323A1 PE 20120323 A1 PE20120323 A1 PE 20120323A1 PE 2011001907 A PE2011001907 A PE 2011001907A PE 2011001907 A PE2011001907 A PE 2011001907A PE 20120323 A1 PE20120323 A1 PE 20120323A1
Authority
PE
Peru
Prior art keywords
sorafenib
trimetoxifenil
phenil
serinamide
metoxy
Prior art date
Application number
PE2011001907A
Other languages
English (en)
Inventor
Brigitte Dermes
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20120323A1 publication Critical patent/PE20120323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMBINACION FARMACEUTICA ANTITUMORAL QUE COMPRENDE: A) AVE8062 DE FORMULA (I) EN FORMA DE HIDROCLORURO; Y B) SORAFENIB EN FORMA DE TOSILATO; EN DONDE EL AVE8062 SE ADMINISTRA POR VIA PARENTERAL Y ANTES QUE EL SORAFENIB EL CUAL SE ADMINISTRA POR VIA ORAL. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE TUMOR SOLIDO, SARCOMA, CANCER DE PULMON, CANCER DE OVARIO, CANCER DE RINON
PE2011001907A 2009-05-07 2010-05-06 Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib PE20120323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
PE20120323A1 true PE20120323A1 (es) 2012-04-17

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001907A PE20120323A1 (es) 2009-05-07 2010-05-06 Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
WO2011158206A1 (en) * 2010-06-18 2011-12-22 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
CA2942039A1 (en) * 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
WO1999051246A1 (fr) * 1998-04-03 1999-10-14 Ajinomoto Co., Inc. Agents antitumoraux
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
PT1407784E (pt) * 2001-06-25 2011-03-03 Ajinomoto Kk Agentes antitumorais
AU2003209118A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
IL216133A0 (en) 2012-01-31
ECSP11011440A (es) 2011-12-30
FR2945210B1 (fr) 2011-07-01
BRPI1014197A2 (pt) 2016-04-26
CR20110573A (es) 2011-12-08
KR20120023754A (ko) 2012-03-13
MX2011011767A (es) 2012-02-28
FR2945210A1 (fr) 2010-11-12
NI201100191A (es) 2012-01-16
EP2427185A1 (fr) 2012-03-14
SG175895A1 (en) 2011-12-29
WO2010128259A1 (fr) 2010-11-11
CL2011002782A1 (es) 2012-03-30
MA33346B1 (fr) 2012-06-01
DOP2011000335A (es) 2011-12-15
CO6390102A2 (es) 2012-02-29
ZA201108110B (en) 2013-01-30
TW201043225A (en) 2010-12-16
CN102438608A (zh) 2012-05-02
UY32618A (es) 2010-12-31
CA2761146A1 (fr) 2010-11-11
EA201171366A1 (ru) 2012-05-30
US20120108641A1 (en) 2012-05-03
AU2010244254A1 (en) 2011-11-24
TN2011000551A1 (fr) 2013-05-24
JP2012526090A (ja) 2012-10-25
AR076848A1 (es) 2011-07-13

Similar Documents

Publication Publication Date Title
PE20120323A1 (es) Combinacion antitumoral que comprende (z)-n-[2-metoxi-5-[2-(3,4,5-trimetoxifenil)vinil] fenil]-l-serinamida y sorafenib
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
BR112014012407A2 (pt) amidas de piridona e análogos exibindo propriedades anti-câncer e anti-proliferativas
EA201270247A1 (ru) Способы применения с-мет-модуляторов
PE20151654A1 (es) Inhibidores de cdc7
CY1118678T1 (el) Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου
CO6592104A2 (es) Compuesto heterociclico
CR20140301A (es) Derivados de betulina
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
UA116467C2 (uk) Модулятори p2x7
IN2014MN02106A (es)
RS54386B1 (en) ANTIVIRAL UNITS
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
CL2008001213A1 (es) Uso de compuestos derivados de piridin-4-il-benceno-1,4-diamino sustituidos por alquindol para preparar un medicamento para el tratamiento de un trastorno proliferativo tal como el cancer.
NZ722345A (en) Pyrazolone compounds and uses thereof
PE20150904A1 (es) Profarmacos de rebamipida novedosos, metodo de preparacion y uso de los mismos
MD3395821T2 (ro) Compuși antitumorali
UA112746C2 (uk) Протиракові стероїдні лактони, ненасичені в положенні 7(8)
EA027986B9 (ru) Соединения триазолона и их применение
EP2580578A4 (en) METHOD AND DEVICES FOR LIGHTING POWER GENERATION FROM INTEGRATED ELECTRODE CHIPS BY CATHODIC AND BIPOLAR IMPULSES
AR092627A1 (es) Derivados glucopiranosidos de urea

Legal Events

Date Code Title Description
FC Refusal